Literature DB >> 18003766

N-acetylcysteine in the prevention of contrast-induced nephropathy.

Steven Fishbane1.   

Abstract

BACKGROUND AND OBJECTIVES: Contrast-induced nephropathy (CIN) is a common clinical problem that is growing in importance as an increasing number of tests and procedures that utilize contrast media are performed. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: The biological and pharmacological properties of n-acetylcysteine (NAC) are reviewed, as well as the current literature relevant to the ability of NAC to prevent CIN.
RESULTS: After publication of a seminal study by Tepel et al. in 2000, there has been a surge in interest regarding the ability of NAC to reduce the risk for CIN. Since then a large number of studies, mostly with relatively small sample sizes, have been published.
CONCLUSIONS: The results have been remarkably varied with some studies finding great efficacy with NAC but most finding no significant benefit.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18003766     DOI: 10.2215/CJN.02590607

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  42 in total

1.  Fructose-1,6-bisphosphate and N-acetylcysteine attenuate the formation of advanced oxidation protein products, a new class of inflammatory mediators, in vitro.

Authors:  Guilherme Vargas Bochi; Vanessa Dorneles Torbitz; Lara Peruzzolo Cargnin; Manuela Borges Sangoi; Roberto Christ Vianna Santos; Patrícia Gomes; Rafael Noal Moresco
Journal:  Inflammation       Date:  2012-12       Impact factor: 4.092

Review 2.  Contrast-induced acute kidney injury and diabetic nephropathy.

Authors:  Andrew D Calvin; Sanjay Misra; Axel Pflueger
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

Review 3.  Contrast medium induced acute kidney injury: a narrative review.

Authors:  Valentina Pistolesi; Giuseppe Regolisti; Santo Morabito; Ilaria Gandolfini; Silvia Corrado; Giovanni Piotti; Enrico Fiaccadori
Journal:  J Nephrol       Date:  2018-05-25       Impact factor: 3.902

4.  Farm animal models of organic dust exposure and toxicity: insights and implications for respiratory health.

Authors:  Chakia J McClendon; Carresse L Gerald; Jenora T Waterman
Journal:  Curr Opin Allergy Clin Immunol       Date:  2015-04

5.  Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury.

Authors:  Antonio Pisani; Massimo Sabbatini; Eleonora Riccio; Roberta Rossano; Michele Andreucci; Clemente Capasso; Viviana De Luca; Vincenzo Carginale; Mariano Bizzarri; Antonella Borrelli; Antonella Schiattarella; Michele Santangelo; Aldo Mancini
Journal:  Clin Exp Nephrol       Date:  2013-06-27       Impact factor: 2.801

6.  Section 3: Prevention and Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

Review 7.  Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines.

Authors:  Fulvio Stacul; Aart J van der Molen; Peter Reimer; Judith A W Webb; Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Peter Aspelin; Marie-France Bellin; Olivier Clement; Gertraud Heinz-Peer
Journal:  Eur Radiol       Date:  2011-08-25       Impact factor: 5.315

Review 8.  Contrast-induced nephropathy: pathogenesis and prevention.

Authors:  Robert E Cronin
Journal:  Pediatr Nephrol       Date:  2009-05-15       Impact factor: 3.714

Review 9.  Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology.

Authors:  Stanley Goldfarb; Peter A McCullough; John McDermott; Spencer B Gay
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

10.  An alternative pathway through the Fenton reaction for the formation of advanced oxidation protein products, a new class of inflammatory mediators.

Authors:  Guilherme Vargas Bochi; Vanessa Dorneles Torbitz; Lara Peruzzolo Cargnin; José Antonio Mainardi de Carvalho; Patrícia Gomes; Rafael Noal Moresco
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.